<DOC>
	<DOCNO>NCT00577109</DOCNO>
	<brief_summary>This single arm study ass efficacy safety combination modify FOLFIRI ( irinotecan , 5-FU leucovirin ) , Avastin cetuximab patient previously untreated metastatic colorectal cancer . Patients receive modify FOLFIRI ( irinotecan 180mg/m2 iv , leucovirin 200mg/m2 iv , 5-FU 400mg/m2 iv ) day 1 2 week cycle , combination Avastin ( 5mg/kg iv day 1 cycle ) cetuximab ( load dose 400mg/m2 follow 250mg/m2 day 3 cycle ) . The anticipated time study treatment disease progression unacceptable toxicity , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Chemotherapy Patients With Previously Untreated Metastatic Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; colorectal cancer ; advanced recurrent disease ; &gt; =1 measurable lesion ; &gt; =6 month since prior adjuvant therapy , &gt; =4 week since prior radiotherapy . previous treatment colorectal cancer ; significant history cardiac disease past 6 month ; invasive malignancy within past 5 year , except nonmelanoma skin cancer , successfully treated cervical prostate cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>